Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
12/10/2023 12:36
Oct 12 (Reuters) - Cyteir Therapeutics Inc CYT.O :
* ONGOING RESULTS FROM A DOSE EXPANSION COHORT OF CYT-0851
IN
COMBINATION WITH CAPECITABINE IN ADVANCED PLATINUM-RESISTANT
OVARIAN CANCER SHOW PROMISING CLINICAL ACTIVITY AND GENERALLY
WELL TOLERATED SAFETY PROFILE
* CYTEIR THERAPEUTICS INC: OVERALL DISEASE CONTROL RATE WAS
91% IN
CAPECITABINE COMBINATION WITH A MEDIAN PROGRESSION-FREE SURVIVAL
OF 170 DAYS
* CYTEIR THERAPEUTICS INC: TWO PATIENTS HAD A CONFIRMED
PARTIAL
RESPONSE BY RECIST AND ONE ADDITIONAL PATIENT ACHIEVED AN
UNCONFIRMED PARTIAL RESPONSE
* CYTEIR THERAPEUTICS INC: TO DATE, CYT-0851 HAS EXHIBITED A
GENERALLY WELL TOLERATED SAFETY PROFILE WITH NO UNANTICIPATED
TOXICITIES OBSERVED
* CYTEIR THERAPEUTICS: CYT-0851 DEMONSTRATED ACTIVITY WITH
CAPECITABINE IN HEAVILY PRETREATED PLATINUM-REFRACTORY OR
-RESISTANT OVARIAN CANCER PATIENTS
Source text for Eikon: ID:nBw4KwxS5a
Further company coverage: CYT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Cyteir Therapeutics
See all newsBrief: Cyteir Announces Timeline For Voluntarily Delisting From Nasdaq
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile